Award
NIH Reporter #1R37CA315256-01
Multi-directed prime-pull cancer immunotherapy using super-adjuvant nanoparticles
Recipient
University of Massachusetts Amherst
Award Amount
$416,468.00
Ceiling
$416,468.00
Awarded
June 29, 2026
Identifier
1R37CA315256-01
The University of Massachusetts Amherst received NIH funding to study nanoparticle-based prime-pull vaccination using synergistic STING and TLR4 adjuvants, with the goal of strengthening anti-tumor immune responses in metastatic melanoma.
Description
Funding for a project developing dual-adjuvant, dual-delivery nanoparticles to combine lymph-node priming and tumor-directed vaccination for cancer immunotherapy, using metastatic melanoma as a model.